CIMIC – Trade Update

Posted on | by Leon Hinde

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

24/4 CIMIC breaks above the 10-day average after forming a new trend low mid-week at $16.86.


CIMIC – Trade Update

Posted on | by Leon Hinde

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

24/4 CIMIC breaks above the 10-day average after forming a new trend low mid-week at $16.86.


Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.